Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Central Nervous System Biomarkers Market Expected To Expand Between 2025 And 2029?
The central nervous system biomarkers market size has experienced substantial expansion over recent years. It is anticipated to increase from $5.58 billion in 2024 to $6.14 billion in 2025, achieving a compound annual growth rate (CAGR) of 9.9%. This historical growth can be linked to heightened concerns about neurological disorders, the extensive prevalence of central nervous system illnesses, an increased need for better diagnosis and treatment, advancements in healthcare infrastructure, and the rising aging population.
The central nervous system biomarkers market is projected for significant expansion in the coming years. Its value is anticipated to reach $8.98 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.0%. This growth during the projection period stems from factors such as the rising incidence of neurological disorders, the escalating need for personalized medical treatments, an expanding elderly demographic, a heightened emphasis on early detection, and the increasing preference for non-invasive diagnostic instruments. Key developments expected during the forecast period encompass novel technological breakthroughs, strategic alliances among biotechnology firms, pharmaceutical enterprises, and other key players, an increase in research concerning cerebrospinal fluid (CSF) and blood-based biomarkers, and the deployment of AI and machine learning algorithms.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12632&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Central Nervous System Biomarkers Industry?
An anticipated increase in neurological illnesses is set to fuel the expansion of the central nervous system biomarker market. These conditions, also termed neurological disorders, encompass a wide spectrum of ailments impacting the brain, spinal cord, and the entire nervous system. Their origins can be diverse, stemming from genetic predispositions, infections, autoimmune reactions, degenerative changes, growths, vascular problems, or physical trauma. Within the context of neurological disorders, central nervous system (CNS) biomarkers are instrumental in facilitating clinical diagnosis, identifying disease risk or predicting outcomes, evaluating the progression of the illness, and monitoring the effectiveness of therapies. These biomarkers are crucial for comprehending such diseases and improving their treatability. For example, data from April 2023, provided by the US government agency, the Centers for Disease Control and Prevention, indicated that approximately 6.7 million Americans aged 65 and above were living with Alzheimer’s disease. This figure is projected to almost triple, reaching 14 million by 2060. Furthermore, the prevalence of the disease doubles every five years after age 65. Consequently, the increasing prevalence of neurological illnesses is a key driver for the expansion of the central nervous system biomarker market.
What Are The Leading Segments Analyzed In The Central Nervous System Biomarkers Market?
The central nervous system biomarkersmarket covered in this report is segmented –
1) By Type: Safety Biomarker; Efficacy Biomarker; Validation Biomarker; Other Types
2) By Disease: Multiple Sclerosis; Alzheimer’s Disease; Parkinson’s Disease; Traumatic Brain Injury; Other Diseases
3) By Application: Drug Discovery And Development; Personalized Medicines; Disease Risk Assessment; Diagnostics; Other Applications
4) By End-Users: Diagnostic Labs; Clinics; Hospitals; Research Centers; Other End-Users
Subsegments:
1) By Safety Biomarker: Toxicity Biomarkers; Adverse Event Biomarkers
2) By Efficacy Biomarker: Pharmacodynamic Biomarkers; Response Biomarkers
3) By Validation Biomarker: Predictive Biomarkers; Prognostic Biomarkers
4) By Other Types: Diagnostic Biomarkers; Biomarkers For Disease Progression
Which Ongoing Trends Are Expected To Shape The Central Nervous System Biomarkers Market Outlook?
A significant trend emerging in the central nervous system biomarker market is the increasing focus on innovative drug approvals. Companies prominent in the central nervous system biomarkers market are prioritizing the development and approval of new drugs to enhance their market standing. As an illustration, in January 2022, Denovo Biopharma LLC, a clinical-stage biopharmaceutical company based in the US, declared that the US Food and Drug Administration (FDA) had approved and authorized its investigational new drug (IND) application for DB104 (liafensine) targeting treatment-resistant depression (TRD). This represents the inaugural biomarker-guided global CNS clinical trial for TRD. Furthermore, it holds the potential to pinpoint patients more likely to benefit from liafensine, paving the way for more tailored treatment approaches. Liafensine functions as a novel compound by elevating dopamine and norepinephrine levels within the brain.
Which Key Players Are Driving Competition In The Central Nervous System Biomarkers Market?
Major companies operating in the central nervous system biomarkers market include F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Abastar Mdx Inc., Banyan Biomarkers Inc., Avacta Group PLC, Geno Technology Inc., Anavex Life Sciences Corp., Alseres Pharmaceuticals Inc., Aposense Ltd., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Abiant Inc., Avid Radiopharmaceuticals Inc., Acumen Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics
Download The Full Report For Exclusive Market Findings:
What Are The Key Regional Factors Influencing The Central Nervous System Biomarkers Market Growth?
North America was the largest region in the central nervous system biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Central Nervous System Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12632&type=smp
Browse Through More Reports Similar to the Global Central Nervous System Biomarkers Market 2025, By The Business Research Company
Generic Central Nervous System Drugs Global Market Report 2025
Biomarkers Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Cancer Biomarker Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model